sh-Polypeptide-71 for Hair Regrowth - Quick Reference Sheet

sh-Polypeptide-71 for Hair Regrowth

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A laboratory-made copy of a human nerve messenger, sold inside multi-ingredient scalp serums at about a hundred dollars a month. The idea is plausible — wider blood vessels, more cell growth, calmer immunity around hair roots — but every observation comes from laboratory dishes. No human study names this ingredient, and the same messenger suppresses hair pigment. (Full Review)

Protocol

Standard at-home regimen
1 mL once daily
One full dropper massaged into a dry scalp over thinning areas and not rinsed. A 50 mL bottle supplies about fifty applications.
In-office device-assisted regimen
Every 2–4 weeks for 12 weeks
A 1927 nm fractional thulium laser or microneedling pass followed immediately by the higher-concentration in-office serum, then maintained at home.
Best time of day
Evening, dry scalp
The serum is left on for hours, and daytime sweat, styling products, and washing remove it. No circadian advantage has been demonstrated.
Time to effect
Best results
12–18 months
Manufacturer's own framing, which implies indefinite continuation. No independent source confirms this timing.
Fuller results
4–6 months
Manufacturer statement. No independent source confirms this timing.
Reduced shedding, visible volume
8–12 weeks
Earliest claimed change. Manufacturer statement; no independent source confirms it.

Benefits

Contraindications
  • History of scalp keratinocyte carcinoma (basal or squamous cell) or scalp melanoma at any time
  • Active scalp infection (bacterial folliculitis, tinea capitis) until a clinician confirms it has cleared
  • Scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia)
  • Moderate-to-severe scalp psoriasis or atopic dermatitis (>10% body surface area or requiring systemic therapy)
  • Pregnancy and lactation, and anyone under 18 years of age
  • Known allergy to curcumin, phenoxyethanol, copper peptides, or any other component of the formulation
Key Interactions
  • Topical minoxidil (Rogaine, Kirkland)
  • Topical prescription retinoids and exfoliating acids (tretinoin, adapalene, glycolic acid, salicylic acid)
  • Over-the-counter medicated shampoos (ketoconazole 1%, selenium sulfide, coal tar, salicylic acid)
  • Microneedling devices and fractional laser (1927 nm thulium)
  • Systemic DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin)
  • Supplements with additive scalp vasodilation (topical caffeine, rosemary essential oil, Ginkgo biloba extract, niacinamide, topical melatonin)
  • Supplements with additive follicular signalling (copper tripeptide-1, biotinoyl tripeptide-1, saw palmetto, oral collagen peptides)
  • Other interventions (platelet-rich plasma injection, low-level laser caps, hair transplantation)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Application-site irritation and contact sensitisation; vasoactive effects at systemic exposure
  • Speculative: Loss of hair shaft pigmentation; amplified cutaneous inflammatory signalling; angiogenic stimulation of undiagnosed scalp lesions

Monitoring

Marker Target Why
Ferritin 70–100 ng/mL Iron stores gate hair shaft production
25-hydroxyvitamin D 40–60 ng/mL Low status tracks with diffuse shedding
TSH 0.5–2.0 mIU/L Thyroid dysfunction causes diffuse hair loss
Serum zinc 90–130 µg/dL Deficiency impairs follicular keratin synthesis
hs-CRP <1.0 mg/L Flags inflammation that both suppresses growth and predicts stinging
Complete blood count with haemoglobin Haemoglobin 13.5–15.0 g/dL (women), 14.5–16.0 g/dL (men) Anaemia produces diffuse shedding that mimics non-response
Free and total testosterone, DHEA-S Mid-reference for age and sex Androgen excess in women drives pattern loss the serum cannot offset
Hair count and shaft diameter at a fixed 1 cm² vertex site No established target exists; change from the individual's own baseline The only direct measure of the outcome being purchased

Cadence: Baseline panel and fixed-site photography before the first application; photography repeats at 12 and 24 weeks, then every six months; the laboratory panel repeats at six months, or sooner if shedding increases, and annually thereafter once values sit in range.

Qualitative Assessment

  • Shedding volume, counted as hairs collected in the shower drain over a fixed washing routine
  • Scalp comfort, specifically itch, stinging, tightness, and flaking during the first two weeks
  • Perceived hair body and styling hold, which changes with shaft calibre before density visibly changes
  • Width of the midline part and the size of the visible scalp show under overhead light
  • Any lightening of new growth at the roots, which would signal the pigmentation concern
  • Adherence, recorded as missed application days per month